发明名称 uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla
摘要 The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof.
申请公布号 BR112013014061(A2) 申请公布日期 2016.09.13
申请号 BR20131114061 申请日期 2011.12.06
申请人 TEVA PHARMACEUTICAL INDUSTRIES LTD. 发明人 DAN BAR-ZOHAR;DINA KOFLER;NORA TARCIC
分类号 A61K31/47 主分类号 A61K31/47
代理机构 代理人
主权项
地址